A current update in COVID-19 associated acute respiratory distress syndrome: Focus on mesenchymal stem cell therapy

Abstract

Indonesia has been fighting the COVID-19 pandemic since the beginning of March 2020, and it doesn’t look that the situation is getting better any soon. Besides the country’s current strategies to minimize the rising mortality rate, a novel therapeutic intervention is required. After a thorough search in several databases, we found stem cells to be a likely candidate. Regardless of the general use of stem cells, studies showed positive results regarding the efficacy of using these in lung injuries. Especially, mesenchymal stem cells (MSCs) are known for their easy accessibility and their diverse mechanisms of action, including MSCs immunomodulatory antiviral effect, and its ability to improve lung function. Moreover, some researches perceived these components to be applicable in COVID-19 patients with end stage acute respiratory distress syndrome (ARDS). While randomized clinical trials are still in progress, many case reports show MSCs to be an advantageous alternative to suppress the cytokine storm and help regulate the immune system. This review summarizes the common functions of MSCs and highlights its therapeutic assets to fully tackle this global pandemic.
 Key word: Mesenchymal Stem Cells; Cell Therapy; COVID-19; SARS-CoV-2; ARDS
 Abbreviations: COVID-19 – Coronavirus Disease; MSC – Mesenchymal Stem Cell; ARDS – Acute Respiratory Distress Syndrome
 Citation: Nugraha D, Kloping NA, Yudhawati R, Purwandhono A, Hidayati HB. A current update in COVID-19 associated acute respiratory distress syndrome: Focus on mesenchymal stem cell therapy. Anaesth. pain intensive care 2020;24(6):---
 Received: , Reviewed: , Revised: , Accepted:

Clinical manifestations of COVID-19 in patients with asthma, hypertension, and diabetes mellitus

“…Patients who have at least one comorbidity or more have poor clinical outcomes [ 7 ]. One of the most frequently observed laboratory abnormalities is a decreased lymphocyte count, which increases the risk of acute respiratory distress syndrome (ARDS) and, thus, the severity of the disease in COVID-19 patients [ 19 – 21 ].…”

Convalescent Plasma Therapy in Severe-Critical COVID-19 Patients at North Kalimantan Regional Public Hospital: Survival Analysis

“…This condition immediately requires the development of costeffective technology platforms for the production of vaccines, drugs, and protein reagents for the precise diagnosis and treatment of the disease (8). In addition, a novel treatment plan is required to lessen the growing number of deaths caused by COVID-19 (9). Since the beginning of March 2020, Indonesia has been fighting the covid-19 pandemic, and the situation does not appear to be improving anytime soon.…”

Effectiveness of convalescent plasma therapy for COVID-19 patients infected with variants of concerns

“…Ever since the first case was confirmed to be positive, measures taken included large scale social restrictions, strict stay-at-home orders, improvement in healthcare services, and provision of personal protective equipment (PPEs) to healthcare workers across the country. 3 'Variants of concern' (VoCs) comprise of SARS-CoV-2 variants that meet the definition of a VoIs (variants of interest) and, through a comparative assessment, have been demonstrated to be associated with increases in transmissibility or detrimental change in COVID-19 epidemiology, increases in virulence or changes in clinical disease presentation, and/or decreases in effectiveness of public health and social measures or available diagnostics, vaccines, therapeutics at a degree of global public health significance. 4 As VoCs have been suspected for the massive spread and higher mortality cases, various studies had introduced the use of convalescent plasma therapy (CPT) as an adjuvant therapy to counter against it.…”